ImpriMed

ImpriMed is conducting a study on feline patients to evaluate non-invasively collected specimens and, with the support of AI, identify biomarkers that may help distinguish IBD from EATL.

Feline IBD and lymphoma have similar signs, making diagnosis difficult. Research and sample donations are improving detection and treatment.

ImpriMed, Inc.'s CEO and co-founder received the 2022 40 Under 40 in Cancer Award. The initiative recognizes contributions to cancer care by people under 40, selected by a panel of oncology professionals.

The company developed and externally validated a multi-institutional machine-learning score that predicts bloodstream infection probability and the causative pathogen's Gram class when a blood culture is ordered.

The study measured patient-derived cells' ex vivo sensitivity to up to 21 anti-cancer drugs and assessed its prognostic utility. Results showed that drug sensitivities can predict clinical outcomes.

The study investigated the relationship between MDR1 mutations and ex vivo drug sensitivities in canine lymphoma patients. MDR1 mutations can alter drug transport and contribute to multidrug resistance.

ImpriMed is hiring in Palo Alto and Seoul across biology, AI/ML, software, and business development to advance precision oncology.

Founded in 2017 in Silicon Valley, ImpriMed uses AI and live-cell testing to predict cancer drug response. Serving veterinary oncology, human medicine, and pharma CRO.

ImpriMed offers veterinary oncology services, human precision medicine, and pharma CRO partnerships, and responds to inquiries within 1–2 business days.

ImpriMed uses live-cell testing and AI to predict drug response for veterinary oncology, human blood cancers, and pharma drug development. Based in Palo Alto & Seoul.

ImpriMed, Inc. (“ImpriMed”) offers comprehensive services to ImpriMed’s veterinarian clinic customers (each a “Clinic Customer”), as set forth in the ImpriMed Service Terms & Conditions (such service referred to herein as the“ImpriMed Service”).

ImpriMed was covered in a News report on recent company activity.

Jun 2024 · NewsNews article

ImpriMed plans to present ex vivo drug sensitivity data related to an acute condition. The report also covers company developments and industry activity.

Jun 2024 · NewsNews article

ImpriMed was covered in a ImpriMed report on company developments and industry activity.

Jun 2024 · ImpriMedNews article

ImpriMed is featured in a news report about its recent company activity and industry developments. The headline describes a new AI service offering personalized drug-response predictions for canine patients with cancer.

Jun 2024 · NewsNews article